NEW YORK (GenomeWeb News – Sequenom today reported preliminary full-year revenue of $162 million, an increase of 81 percent over the prior year but shy of consensus analyst estimates of $164.4 million.

Alongside its preliminary financial results, the company said that it is expanding its noninvasive prenatal testing menu by developing a "low cost test on an alternative platform" that it plans to launch by the end of the year. Sequenom's MaterniT21 Plus prenatal trisomy test currently runs on the Illumina sequencing platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.